Sessions are available to view via livestream, in the parents room
Welcome to Country
Presidents Welcome
Dr Rob O'Sullivan
Session Title: Parkinsons disease and device assisted therapies - role in geriatric patients.
Speaker: Raju George
This session will provide a comprehensive overview of Parkinson’s disease, with a focus on recognizing both motor and non-motor symptoms. Attendees will gain insight into current oral treatments and explore advanced, device-assisted therapeutic options tailored for geriatric patients. Emphasis will be placed on individualized care strategies to optimize outcomes in older adults living with Parkinson’s.
New Curriculum Presentation (30 mins)
Q&A (30 mins)
Session Title: Current Australian "real world" clinical impact studies of Blood Based Biomarkers for AD. Speaker: Professor Christopher Rowe Plasma pTau217 has emerged as an accurate test for Alzheimer's disease with approximately 90% accuracy, considerably higher than the 70% achieved using clinical criteria alone. This plus the relatively low cost (likely to eventually be $200-300) and the access and equity advantages, make a compelling case for inclusion in clinical practice. Either in collaboration with overseas companies or through use of existing Australian research facilities who have single molecular array (Simoa) technology, plasma pTau217 is now being evaluated for accuracy and impact in real world Australian clinical practice. The MRFF/NHMRC funded EDD study based at the Florey Institute, Melbourne is assessing diagnostic and management impact in 500 memory clinic patients and comparing to FDG and amyloid PET. The Australian Dementia Network (ADNeT) recently completed a pTau181 study in 120 memory clinic patients across sites in Sydney, Melbourne and Hobart and is now running a pilot of pTau217 with 70 GPs in Adelaide, Newcastle and Melbourne funded by the Department of Health and Aged Care. Other studies are looking at the value of plasma neurofilament light (NfL), a measure of neurodegeneration, to assist diagnosis of dementia beyond AD. The field of Blood Based Biomarkers for AD is progressing rapidly and BBB assisted diagnosis of AD is likely to be part of routine Australian clinical practice in the near future.